NASDAQ:IDXX

IDEXX Laboratories Stock Forecast, Price & News

$678.72
+0.19 (+0.03 %)
(As of 08/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$666.85
$688.69
50-Day Range
$547.56
$704.16
52-Week Range
$347.54
$706.95
Volume354,084 shs
Average Volume409,502 shs
Market Capitalization$57.88 billion
P/E Ratio80.90
Dividend YieldN/A
Beta0.91
30 days | 90 days | 365 days | Advanced Chart
Receive IDXX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.


IDEXX Laboratories logo

About IDEXX Laboratories

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.01 out of 5 stars

Medical Sector

568th out of 2,226 stocks

Diagnostic Substances Industry

9th out of 38 stocks

Analyst Opinion: 1.4Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions

Is IDEXX Laboratories a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IDEXX Laboratories stock.
View analyst ratings for IDEXX Laboratories
or view top-rated stocks.

What stocks does MarketBeat like better than IDEXX Laboratories?

Wall Street analysts have given IDEXX Laboratories a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but IDEXX Laboratories wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is IDEXX Laboratories' next earnings date?

IDEXX Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for IDEXX Laboratories
.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings results on Friday, July, 30th. The company reported $2.34 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $2.01 by $0.33. The firm earned $826.14 million during the quarter, compared to analyst estimates of $794.64 million. IDEXX Laboratories had a trailing twelve-month return on equity of 115.28% and a net margin of 23.89%. The company's quarterly revenue was up 29.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.72 EPS.
View IDEXX Laboratories' earnings history
.

How has IDEXX Laboratories' stock been impacted by Coronavirus (COVID-19)?

IDEXX Laboratories' stock was trading at $245.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IDXX stock has increased by 176.4% and is now trading at $678.72.
View which stocks have been most impacted by COVID-19
.

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories declared that its Board of Directors has approved a stock buyback program on Wednesday, February 12th 2020, which permits the company to buyback 5,000,000 outstanding shares, according to EventVestor. This buyback authorization permits the company to buy shares of its stock through open market purchases. Stock buyback programs are often a sign that the company's board of directors believes its stock is undervalued.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories issued an update on its FY21 earnings guidance on Friday, July, 30th. The company provided earnings per share guidance of $8.20-8.36 for the period, compared to the Thomson Reuters consensus estimate of $8.17. The company issued revenue guidance of $3.170-3.205 billion, compared to the consensus revenue estimate of $3.15 billion.

What price target have analysts set for IDXX?

4 brokers have issued 1-year target prices for IDEXX Laboratories' stock. Their forecasts range from $422.00 to $750.00. On average, they anticipate IDEXX Laboratories' share price to reach $580.67 in the next year. This suggests that the stock has a possible downside of 14.4%.
View analysts' price targets for IDEXX Laboratories
or view top-rated stocks among Wall Street analysts.

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the following people:
  • Mr. Jonathan J. Mazelsky, Pres, CEO & Director (Age 60, Pay $2.54M)
  • Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 59, Pay $1.35M)
  • Ms. Sharon E. Underberg, Sr. VP, Gen. Counsel & Corp. Sec. (Age 60, Pay $881.05k)
  • Mr. Jonathan W. Ayers, Sr. Advisor & Director (Age 65, Pay $169.87k) (LinkedIn Profile)
  • Mr. James F. Polewaczyk, Exec. VP & Chief Commercial Officer (Age 57, Pay $1.11M) (LinkedIn Profile)
  • Mr. Michael J. Lane, Exec. VP and GM of Reference Laboratories & Information Technology (Age 53, Pay $1.11M)
  • Mr. John Hart, Sr. VP of Worldwide Operations
  • Mr. Jeffery D. Chadbourne, Sr. Director of Accounting & Financial Reporting (Age 45)
  • Mr. Ken Grady, Sr. VP & Chief Information Officer
  • Ms. Kathy V. Turner, Chief Marketing Officer & Sr. VP (Age 57) (LinkedIn Profile)

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories CEO Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among IDEXX Laboratories' employees.

Who are some of IDEXX Laboratories' key competitors?

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Square (SQ), The Walt Disney (DIS) and Shopify (SHOP).

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Alliancebernstein L.P. (1.44%), Sumitomo Mitsui Trust Holdings Inc. (0.31%), Welch & Forbes LLC (0.21%), Manning & Napier Group LLC (0.18%), Howland Capital Management LLC (0.12%) and Beacon Investment Advisory Services Inc. (0.12%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, Jay Mazelsky, Jonathan Jay Mazelsky, Jonathan W Ayers, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends for IDEXX Laboratories
.

Which major investors are selling IDEXX Laboratories stock?

IDXX stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Sumitomo Mitsui Trust Holdings Inc., Whittier Trust Co., Howland Capital Management LLC, Manning & Napier Group LLC, Schaper Benz & Wise Investment Counsel Inc. WI, Beacon Investment Advisory Services Inc., and Teamwork Financial Advisors LLC. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson, and Sophie V Vandebroek.
View insider buying and selling activity for IDEXX Laboratories
or view top insider-selling stocks.

Which major investors are buying IDEXX Laboratories stock?

IDXX stock was bought by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, State of Alaska Department of Revenue, Zurcher Kantonalbank Zurich Cantonalbank , Moody Lynn & Lieberson LLC, 44 Wealth Management LLC, CHICAGO TRUST Co NA, IFM Investors Pty Ltd, and Fisher Asset Management LLC.
View insider buying and selling activity for IDEXX Laboratories
or or view top insider-buying stocks.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $678.72.

How much money does IDEXX Laboratories make?

IDEXX Laboratories has a market capitalization of $57.88 billion and generates $2.71 billion in revenue each year. The company earns $581.78 million in net income (profit) each year or $6.71 on an earnings per share basis.

How many employees does IDEXX Laboratories have?

IDEXX Laboratories employs 9,300 workers across the globe.

When was IDEXX Laboratories founded?

IDEXX Laboratories was founded in 1983.

What is IDEXX Laboratories' official website?

The official website for IDEXX Laboratories is www.idexx.com.

Where are IDEXX Laboratories' headquarters?

IDEXX Laboratories is headquartered at ONE IDEXX DRIVE, WESTBROOK ME, 04092.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at (207) 556-0300 or via email at [email protected]


This page was last updated on 8/2/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.